Cubist Systematic Strategies, LLC Passage Bio, Inc. Transaction History

Cubist Systematic Strategies, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$0.86 - $1.73 $9,709 - $19,531	11,290 New	11,290 $15,000
Q1 2023 May 15, 2023	SELL	$0.96 - $1.88 $3,797 - $7,437	-3,956 Reduced 28.09%	10,129 $9,000
Q4 2022 Feb 14, 2023	SELL	$1.06 - $1.48 $26,632 - $37,185	-25,125 Reduced 64.08%	14,085 $19,000
Q3 2022 Nov 14, 2022	SELL	$1.22 - $2.48 $22,460 - $45,656	-18,410 Reduced 31.95%	39,210 $49,000
Q2 2022 Aug 15, 2022	SELL	$1.63 - $3.46 $8,943 - $18,985	-5,487 Reduced 8.69%	57,620 $136,000
Q1 2022 May 16, 2022	BUY	$2.66 - $6.49 $37,178 - $90,710	13,977 Added 28.45%	63,107 $196,000
Q4 2021 Feb 14, 2022	BUY	$6.24 - $10.2 $153,641 - $251,144	24,622 Added 100.47%	49,130 $312,000
Q3 2021 Nov 15, 2021	SELL	$9.73 - $15.52 $183,313 - $292,396	-18,840 Reduced 43.46%	24,508 $244,000
Q2 2021 Aug 16, 2021	BUY	$12.44 - $19.45 $405,407 - $633,856	32,589 Added 302.9%	43,348 $574,000
Q1 2021 May 17, 2021	BUY	$16.24 - $29.83 $174,726 - $320,940	10,759 New	10,759 $188,000

38.7M

7.7K

Ticker PASG
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,463,200
Market Cap $35.9M
Description
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 ...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.